HempNewsBreaks

FridayMar 25, 2022 2:40 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic About Its Upcoming, Largest-Ever Hypertension Study

Lexaria Bioscience Corp. (NASDAQ: LEXX) remains committed to enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs. “Through its patented DehydraTECH(TM) drug delivery technology that began development in 2014, the company is offering potential solutions for conditions including, but not limited to hypertension, smoking cessation, anti-viral treatments, and other drug classes,” reads a recent article. The piece discusses significant developments Lexaria has made with its HYPER-H21-4 clinical study on hypertension and heart disease treatment using DehydraTECH-CBD. Given the success of previous studies, the company announced plans for more trials over 2022. “During 2021, we completed research &…

Continue Reading

FridayMar 25, 2022 2:22 pm

HempNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Committed to Execute More Programs to Grow Market Reach and Product Portfolio

InMed Pharmaceuticals (NASDAQ: INM) President and CEO Eric A. Adams recently hosted a conference call and webcast in which he emphasized the company’s successful product diversification and strategic acquisition achievements. He expressed his optimism at the company’s expansion into the health and wellness sector as an ingredient supplier and the integration of BayMedica’s operations and team into its ongoing activities. A recent article reads: “While noting how recent product launches have allowed the company to top its revenue estimates, Mr. Adams was also keen to point out its ongoing commitment to launch even more products in the coming months. He…

Continue Reading

FridayMar 18, 2022 11:26 am

HempNewsBreaks – Red White & Bloom Brands Inc.’s (CSE: RWB) (OTCQX: RWBYF) Acquisition Strategy Spearheading Expansion, Premium Inventory Production

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), a premium cannabis brand multistate operator, has been building assets steadily in Michigan, Florida, Illinois, Massachusetts, and Arizona, while working to establish the quality and consistency that wellness consumers seek. The company announced full licensing for manufacturing both medical and adult-use cannabis products in Michigan in January, along with the closing of a lease assignment for a 15,000-square-foot manufacturing, processing and distribution facility in the city of Warren. A recent article reads: “The manufacturing facility is a key part of RWB’s acquisition strategy for 18 Michigan dispensaries, four cultivation facilities and…

Continue Reading

WednesdayMar 16, 2022 2:28 pm

HempNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Launching Additional Rare Cannabinoids in Response to Inbound Demand

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids, has dedicated itself to developing new therapeutic alternatives for the treatment of conditions with high unmet medical needs. The manufacturing process used by InMed and its recently acquired subsidiary BayMedica is unparalleled in the industry. “There is no ‘one-size-fits-all’ approach to cannabinoid manufacturing, so multiple avenues are required to realize the maximum outcome for the targeted cannabinoid. InMed and BayMedica, like a well-oiled machine, work together using biosynthesis, chemical synthesis and the proprietary IntegraSyn(TM) manufacturing models,” a recent article explains. “Together,…

Continue Reading

WednesdayMar 09, 2022 2:20 pm

HempNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) in the Driver’s Seat Across One of the Country’s Largest, Fastest-Growing Cannabis Markets

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) recently announced it had received all regulatory approvals and closed its acquisition of PharmaCo, a Michigan-based marijuana company. This acquisition expands RWB’s footprint within the state, having initially only had a single product line in this market – the Platinum Vape(R) brand. Following the acquisition, RWB now controls all aspects of its Michigan operations. “This successful acquisition gives RWB access to 22 owned properties, including nine dispensaries and three cultivation sites in Glendale, Marquette and Au Gres… Going forward, RWB looks to execute its initiatives that include extending its branded product…

Continue Reading

FridayMar 04, 2022 2:14 pm

HempNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) On Path Toward Improved Margins Through Vertical Integration

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), a cannabis and CBD product brand builder with a presence in California, Arizona, Oklahoma, Illinois, Michigan, and Florida, most recently celebrated the news that Michigan had granted it adult recreational use prequalification status for manufacture, followed by full licensing to make both medical and adult-use cannabis products in the state. “The company’s lease assignment for a 15,000-square-foot manufacturing and processing facility in the city of Warren led to the launch of operations there [in January], with ‘all necessary equipment already installed and inspections completed’ for medical and adult-use products,” a recent…

Continue Reading

ThursdayMar 03, 2022 3:01 pm

HempNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expanding Portfolio, Presence in Growing Rare Cannabinoid Market

InMed Pharmaceuticals (NASDAQ: INM) is uniquely positioned to leverage the growing worldwide awareness of the potential of cannabinoids and the rising demand for rare cannabinoids. The company has begun this year on a high, following the 2021 acquisition of BayMedica and the launch of cannabicitran (“CBT”) sales. “With the launch of business-to-business sales of CBT in the health and wellness sector, InMed has further expanded its portfolio and its presence in the growing rare cannabinoid market,” reports a recent article. “CBT is the first of several new products InMed is planning to launch in the first half of 2022 in…

Continue Reading

ThursdayMar 03, 2022 2:43 pm

HempNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates Faster, Higher Overall Delivery of Sildenafil into Bloodstream

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently released positive results from an animal study that evaluated DehydraTECH(TM) processing of the phosphodiesterase inhibitor (“PDE5 inhibitor”) sildenafil as potential use in the management of erectile dysfunction. “A clear trend emerged during the course of the study – a faster and higher overall delivery of sildenafil into the bloodstream. During the animal study, it was determined that in as little as four minutes of dosing, the DehydraTECH formulation of sildenafil delivered 74% more of the PDE5 inhibitor into the bloodstream on average than the concentration-matched, generic control formulation. Within seven minutes, the DehydraTECH-sildenafil formulation…

Continue Reading

FridayFeb 25, 2022 1:34 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Optimistic of Positive Study Results, Eyes ‘Most Exciting Year Ever’

Lexaria Bioscience Corp. (NASDAQ: LEXX) achieved myriad milestones in 2021, with CEO Chris Bunka noting in an annual letter to shareholders that January 2021 marked the birth of a modern version of the company. A recent article contains excerpts from the letter, in which Bunka writes, “During 2021, we completed research & development (‘R&D’) and validating work equal to or greater than all the combined amount previously completed since 2018! We have conducted studies across broad areas of interest but also concentrated in specific areas where we have supportive data,” In 2021, Lexaria’s most significant area of investigation was DehydraTECH(TM)-processed…

Continue Reading

FridayFeb 18, 2022 1:57 pm

HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Is World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Technology

Lexaria Bioscience Corp. (NASDAQ: LEXX) commented on an independent study headed by lead research scientist Dr. Richard van Breeman, which discovered that cannabinoids can block cellular entry of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its emerging variants. The study showed that smoking and vaping are likely ineffective measures, whereas oral delivery methods are. “As a company, Lexaria is already actively exploring and researching DehydraTECH(TM)-enabled cannabinoid formulations across various potential therapeutic applications, including oral formulations that are being prepared for registered clinical trials as a possible new pharmaceutical product,” reads a recent article. “In response to the study, Chris…

Continue Reading